September 19, 2025Frontiers in MicrobiologyOpen Access

Preliminary exploration of the ability of HUC-MSCs to restore the lung microbiota and related metabolite disorders in IPF treatment: combining 16S sequencing and metabolite analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Preclinical study shows HUC-MSCs improve lung microbiota and metabolic dysbiosis in mice with IPF, suggesting potential therapeutic pathways.

HUC-MSCs treatment restored alveolar morphology and reduced inflammatory cytokines in IPF model mice.
16S rDNA sequencing indicated decreased diversity indices of lung microbiota after HUC-MSCs treatment.
Notable differences in metabolites included organic acids and lipids, suggesting antifibrotic effects of HUC-MSCs.
Findings indicate that IPF in mice is connected to microbial and metabolic dysbiosis, with HUC-MSCs providing potential treatment insights.

Zhou et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Preclinical study shows HUC-MSCs improve lung microbiota and metabolic dysbiosis in mice with IPF, suggesting potential therapeutic pathways.